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Objective(s): It has been reported that the mutation of the pre-core (PC) and basal-core promoter 
(BCP) may play an important role in the development of HBV-related hepatocellular carcinoma 
(HCC). In this study the PC and BCP mutations were investigated in chronic HBV patients. 
Materials and Methods: In this study, 120 chronic HBV patients from Golestan, Northeast of Iran 
who were not vaccinated against HBV, were recruited from the year 2008 to 2012. HBV-DNA 
extraction from plasma and PCR were performed and positive PCR products were subjected to 
automated sequencing.  
Results: One hundred out of 120 (83.3%) patients were HBeAg negative. Comparison of our 
nucleotide sequences with reference sequence showed high rate mutation in BCP and PC region 
(96.66%). Frame shift mutation was found in 78 (65%) of patients in BCP region, among them 8 
(6.6%) patients showed mutation in PC region. 
Conclusion: Our results demonstrated high rate of mutations in BCP and PC regions among HBV 
chronic patients in Northeast of Iran. 
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Introduction 
Currently, Hepatitis B Virus (HBV) infection is a 
global health problem, and more than 350 million 
people around the world are chronic carriers of this 
virus (1). Because of the spontaneous error rate of 
viral reverse transcriptase, the hepatitis B virus 
(HBV) genome evolves during the course of infection 
under the antiviral pressure of the host immunity 
(2). These HBV variants could display alterations in 
epitopes important to the host immune recognition, 
resulting in enhanced virulence with increased 
replication of HBV, resistance to antiviral therapies, 
or facilitated cell attachment and penetration (3). 
HBV genome has 4 open reading frames (ORFs), 
including envelope genes coding region (pre-s1, pre-
s2 and s), pre-core (pc) and core (c), polymerase (p), 
x gene coding region (4). The HBV x gene (HBx) is a 
16–18 kDa protein, a transcriptional transactivator 
and can positively regulate the transcription of a 
wide variety of viral and cellular promoters (5). The 
observation which reported that HBx transactivates  
several cellular genes regulating cell growth suggests 
that HBx may induce uncontrolled cell proliferation 
(6). HBx is a multi-functional protein that plays a role 
in the development of hepatocellular carcinoma 
(HCC). The basal-core promoter (BCP) is the minimal 
essential promoter sequence accurately mapped 
from nucleotide 1742 to 1849 of HBV complete 
genome and overlaps with the x gene region 
(nucleotide 1374-1836). Since the x gene overlaps 
with the BCP region, mutations in the x region will 
also have specific effects on BCP region (7). T-A 
mutations in BCP are frequent in all genotypes while 
other mutations seem to be more related to specific 
genotypes (8). Pre-core (PC) variants are more 
common among patients with genotype D (65-75%) 
than genotype A (9-18%) (9,10). Isolates with 
transversion at A1762T together with G1764A 
mutations in the BCP are often present in hepatitis B 
carriers with chronic hepatitis, fulminant hepatitis, 
HCC and less often in inactive carriers and immune 
suppressed patients (11).  
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The most frequently observed mutation in the 
PC region is a G-A change at nucleotide 1896 
resulting in a stop codon and hence, leading to 
premature termination of the PC/Core protein 
construction, which is the precursor of HBeAg (12). 
However, this mutation is located within the 
epsilon (ε) structure, a highly conserved stem-loop 
essential for initiation of encapsidation within the 
viral replication cycle. In order to stabilize the ε 
structure, the nucleotide at position 1896 is paired 
with the nucleotide at position 1858, which 
naturally is a thymidine (T) in genotypes B, D, E, 
and G and a cytosine (C) in genotype A (13). In an 
experimental study, the 1762 and 1764 mutations 
reduced the transcription of pre-core mRNA by 
interfering with the binding of transcription 
factors, thus, supporting the assumption that these 
mutations down-regulate HBeAg synthesis (14). 
Moreover, it was also frequently found in both 
HBeAg-positive and HBeAg-negative chronic 
hepatitis (15). Iran is considered as a country with 
low endemicity of chronic HBV infection (16). Our 
previous study in Golestan province showed higher 
prevalence of HBV infection and HBV S gene 
mutation comparing to other parts of Iran (17, 18). 
In this study, the PC and BCP mutations in chronic 
HBV patients in Golestan province of Iran was 
investigated. 
 
Materials and Methods 
Sample selection 
A total of 120 patients with proven chronic HBV 
infection for more than two years, were chosen 
according to clinical and paraclinical evidence from 
Golestan province, Iran from the year 2008 to 
2012. 
None of the patients were vaccinated for HBV or 
had antiviral therapy; all patients had negative 
results for antibodies against hepatitis C, hepatitis 
D and Human Immunodeficiency Virus. The 
research project received the confirmation of the 
Ethics Committee and all the patients signed the 
testimonial letter. Blood samples were collected in 
the EDTA 5% anti-coagulant and plasma was 
separated for further examination. 
 
HBV infection marker detection 
The HBV serological markers (HBeAg) were 
tested using commercially available enzyme-linked 
immune sorbent assay kits (DIALAB GmbH, 
Germany).  
 
DNA extraction 
HBV-DNA was extracted from 200 μl of each 
plasma sample using QIAamp DNA Mini Kit 
(QIAGEN, Hamburg, Germany) following the 
manufacturer instruction and extracted DNA was 
stored at -20°C for PCR process. 
Table 1. Oligonucleotide primers used for PCR and sequencing of 
BCP and Pre core region of Hepatitis B (19) 
 
Name Sequence 5' to 3' Base position 
HBc-F ACCTTGAGGCATACTTCAAA 1689-1708 
HBc-R CAGAATAGCTTGCCTGAGTGC 2058-2078 
 
Primer selection 
Suitable primers were selected to achieve 
optimum PCR sensitivity and the BCP and PC region 
amplification. Following primers listed in Table 1 
yielded 390 bp amplification according to nucleotide 
position 1689 to 2078. 
 
PCR and DNA amplification 
Amplification mixture contained: 100 ng of 
extracted DNA 1X PCR buffer, 1.5 mM MgCl2, 0.2 mM 
dNTP, 2.5 U Taq DNA polymerase (QIAGEN, 
Hamburg, Germany) and 0.4 pmol/μl of each primer 
in a total volume of 50 μl with distilled water. The 
PCR profile started with an initial 5 min denaturation 
at 95°C, followed by 30 cycles of amplification 
including denaturation for 1 min at 95°C, primer 
annealing for 1 min at 55°C and extension for 2 min 
at 72°C, with a final extension at 72°C for 5 min. The 
390 bp amplification products were analyzed by gel 
electrophoresison 1% agarose gel stained with 
ethidium bromide to determine HBV-DNA positive 
and negative samples. 
 
DNA sequencing and mutation analysis 
The positive PCR products were subjected to 
automated sequencing (Macrogen Inc., Korea).          
Then, nucleotide sequences were aligned with 
standard hepatitis B sequence, [Accession number: 
AB033559] from Gene Bank database, for mutation 
detection and analysis (20). All data that were 
collected from the study were analyzed using 
SPSS.16 software. 
One of the samples with critical mutations in BCP 
and PC region was registered in NCBI under the 
accession number: KC928094 
 
Results 
The mean age of patients was 36.8 year, 74% of 
them were male and 26% were female. All of the 
patients were HBsAg positive and 100 out of 120 
(83.3%) patients were HBeAg negative. Isolates 
belonged to genotype D subgenotype D1, subtype 
ayw2 according to our previous study (18). 
Comparison of our nucleotide sequences with 
reference sequence showed high rates of mutations 
with a frequency of 97.5% and 99.2% in BCP and PC 
regions, respectively. In BCP region A1762T and 
A1762G mutations were detected in 25 (20.83%) 
and 5 (4.16%) of patients, respectively. The most 
important mutations detected in BCP were the 8 bp 
nucleotide deletion from 1763 to 1770 which            
were observed in 7 (5.83%) patients. In the case of 
 Mutations in PC and BCP Regions of Hepatitis B Virus         Moradi et al 
 
 Iran J Basic Med Sci, Vol. 17, No. 5, May 2014   
 
372 
Table 2. Frequency and position of point mutations in pre-core (PC) and basal-core promoter (BCP) of HBV 
mutations in PC region, G1896A was detected as the 
most prevalent mutation in 44 (36.66%) patients 
leading creation of stop codon at the 28th amino acid 
of PC region in 39 (32.50%) of patients which 41 
(93.18%) of them were HBeAg negative. Frame shift 
mutation was found in 78 patients (65%) in BCP 
region, but this rate of mutation in PC region was 
seen only in 8 patients (6.6%). 
 
HBeAg positivity and BCP and PC mutations 
Our results showed that among 31 cases with 
A1762T and 44 cases with G1764A point mutations 
in BCP region of HBV, 24 (77.4%) and 34 (77.27%) 
were found in HBeAg negative patients, respectively. 
In the case of mutations in PC region, G1896A was 
detected as the most prevalent mutation in 44 
patients from which 41 (93.18%) were HBeAg 
negative (Table 2). 
 
Point mutations in basal-core promoter (BCP) region 
Our findings demonstrated the occurrence of 59 
point mutations including 21 (35.6%) cases as 
missense mutation (with amino acid altering) and 38 
(64.4%) cases as silent mutation (without amino acid 
altering) in BCP region. These mutations occurred in 
area of BCP which have overlap with X region of HBV 
(HBx). Distribution of single, double, triple, 
quadruple, and more than quadruple point 
mutations in the BCP region were 5 (4.2%), 4 (3.3%), 
9 (7.5%), 6 (5%) and 8 (6.7), respectively. Mutations 
at T1753G and T1753C of BCP region were seen in 
10 (8.33%) and 12 (10%) cases, respectively, which 
caused I127C amino acid mutation in 27 (22.5%) of 
patients. A1762T and A1762G mutations were 
detected in 25 (20.83%) and 5 (4.16%) of patients, 
respectively, which affected the amino acid L130M in 
10 (8.33%) patients. G1764A, G1764T and G1764C 
substitutions were seen in 24 (20%), 16 (13.33%) 
and 4 (3.33%) cases, respectively, which caused 
V131I change in 9 (7.5%) patients (Table 3). 
The most important mutations detected in BCP 
were the 8 bp nucleotide deletion from 1763 to 1770 
which was observed in 7 (5.83%) patients. Figure 1 
shows the distribution and frequency of amino acid 
substitutions in BCP and x region of HBV in chronic 
patients. 
 
Point mutations in precore (PC) region 
Among 78 point mutations in PC region, 26 
(33.3%) occurred as silent mutation and 52 (66.7%) 
as missense mutation. In the case of point mutation 
distribution, 49 (40.8%), 21 (17.5%), 20 (16.66%) 
and 21 (17.4) cases showed double, triple, quadruple 
and more than quadruple mutations in the 
sequenced region of PC region, respectively. 
Substitution at G1896A was seen in 44 (36.66%) 
leading to the creation of stop codon in the 28th 
amino acid of PC region in 39 (32.50%) of patients. 
The most prevalent mutations in PC region                       
at the level of amino acid substitution, were A64S  and 
 
Table 3. The rate of basal-core promoter (BCP) and pre-core 
(PC) mutations in chronic patients and their HBeAg result 
HBV PCregion BCP region 
No. (%) 
Frequency of 
point mutation 
position No. (%) 
Frequency of 
point mutation 
position 
49 (40/83%) 2 A64S, D69E 5 (4/16) 1 C148W, R128D, L141W, C137G, V131L 
21 (17/5%) 3 
G29D,A64S, D69E, 
C12stop,P15A,E37Q, A87P, Q2E, 
W28stop 
4 (3/33) 2 
V142G,N149G, L134G,L141W, 
E122G,V131L, K140F,V142G 
20 (16/66%) 4 
S13T,V17I, Q2stop, A64S,Y67F,D69E, 
G29D, M1L,Q2R, W28stop, 
P79A,T41S, ,I32L, S50H, Q86K, A87P 
9 (7/5) 3 
C137G,L141W,C143stop, 
K130E,V133L,L134W, K140F, 
W120G,V131L, E126C,I127S,R128S, 
W120G,E121R,E122S, L123V 
14 (11/66%) 5 
M1L,S13T, V17I, W28stop, A64S, 
D69E, T41S,S78T,Y67F,G29D, 
A87P,S50A, V56L,L60Q, E72K,P79A, 
S78T, V42L 
6 (5) 4 
W120D,E121G,E122R,L123V, 
C137G,K140F,L141W,N149D, 
R128G,V131L,I127L,K130M,, 
D119A,V142G 
5 (4/16%) 6 
G29D,V42L,A64S,D69E,A87P, M1L, 
Y67F, P74Q,G29D,S50Q, S78T, T41S, 
S50T, S13T,V17I,W28stop,E37K  
4 (3/33) 5 
E122R,L123V,I127S,K130M,V131I, 
W120stop,A146S, E125G,E126G,I127D  
2 (1/66%) 7 
S13T,V17I,W28stop,S78T,A87P,T41S, 
A64S,Y67F,D69E,Q86K,A87P 
4 (3/335) 6 
E126R,I127R,R128stop,L129V,K130M,
V131I, E122R,L123V, 
K130M,V131I,A146S, E121R,E125G, 
W120D 
4 (3/33) 7 
E121G,R128D,L129stop,K130I, 
C137E,R138W, W120D, 
E122R,L123S,E125G,E126G,I127D, 
L134stop 
101 (100%)   36 (100)   
      
Total mutation HBeAg- HBeAg+ Mutation 
31(100%) 24 (77.4%) 7 (22.6%) A1762T 
44 (100%) 34 (77.27%) 10 (22.73%) G1764A 
44 (100%) 41 (93.18%) 3 (6.82%) G1896A 
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Figure 1. Frequency and distribution of amino acid substitution in X gene 
 
 
D69E as they were detected in 102 (85%) and 99 
(82.5%) of patients, respectively. Figure 2 illustrates 
the rate of mutation in different amino acids of PC 
region of HBV in chronic patients. 
 
Discussion 
HBV core promoter overlaps partially with HBx 
coding sequence, so, the nucleotide mutations in core 
promoter induce HBV X protein substitution (21). 
Since HBV genotypes are not uniformly distributed 
around the world, pre-core mutants also have a 
particular distribution, being more frequent in some 
regions such as Asia and the Mediterranean basin, 
where genotypes B, C, or D are predominant, and 
rarely in North America and Europe, where genotype 
A is commonly found (22). This study was designed 
to determine the BCP and CP mutations in patients 
infected with HBV genotype D and its distribution in 
HBeAg negative cases using sequencing and 
alignment with standard sequence. 
As it was shown in the results, genotype D was 
dominant type of HBV in our study and overall 
prevalence of BCP and PC mutation was 99.2% and 
97.5%, respectively. It has been shown that the 
prevalence of PC and BCP mutations depends on HBV  
genotypes, and these mutations are related to 
fulminant and severe hepatitis and hepatocellular 
carcinoma (23-26). 
The high rate of mutations in PC and BCP region of 
HBV genotype D patients in compare with other 
genotypes has been reported from different studies in 
Brazil (22, 27, 28) and Netherland (29). In contrast with 
our data a report from UAE revealed low rate of 
mutation in precore (58.0%) and Basal Core Promoter 
(25.3%) regions (30). 
The G1896A mutation in PC has been found to be 
the most common mutation in chronic HBeAg-negative 
patients (31). This mutation creates a stop codon that 
prevents translation of the pre-core protein and 
terminates the production of HBeAg. However, these 
patients continue to synthesize HBV DNA at sufficient 
levels to continuously damage liver and progress 
toward cirrhosis (32). Median prevalence of the 1896 
PC mutation in HBeAg-negative adults was reported to 
be 50% in Asia, 92% in the Mediterranean, and 24% in 
America (33). The frequency of the 1896 PC mutation 
varies geographically and primarily depends on             
the genotype of HBV (34, 35). The present study 
showed substitution at G1896A in 44 (36.66%) patients 
from which, 41 (93.18%) were HBeAg negative. In 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Figure 2. Frequency and distribution of amino acid substitution in PC region 
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agreement with our results, a study done in Brazil 
showed that the G1896A pre-core mutation occurred 
in 36% of Brazilian patients with chronic hepatitis B, 
among which, 58.6% were HBeAg-negative (36). 
Higher rate (95.3%) of the G1896A mutation was 
also reported in the HBeAg negative group (37). The 
e antigen is an important target for cell-mediated and 
antibody-mediated immune responses, so that the 
inhibition of e antigen production by pre-core 
mutants may help the virus to evade the host 
immune response (38). Hence, the occurrence of the 
pre-core mutation seems to be a strategy of viral 
selection secondary to the immunological pressure 
against HBV (39). In contrast with our results the 
study from Sweden determined that none of six 
genotype D isolates showed the PC stop codon 
mutation at nt 1896 during 17 month follow-up of 
after anti HBe seroconversion (40). 
The most common BCP mutation is the double 
A1762T and G1764A nucleotide exchange, which 
results in a decrease of up to 70% of HBeAg 
expression (41). These mutations reduced the 
transcription of pre-core mRNA by interfering with 
the binding of transcription factors, thus, supporting 
the assumption that these mutations down-regulate 
HBeAg synthesis (42). Results of present research 
showed both BCP mutations at A1762T (36.66%) 
and G1764A (25%) of patients and 19.16% showed 
A1762T/G1764A double mutations from which 24 
(77.4%) and 34 (77.27%) were seen in HBeAg 
negative patients, respectively. These are in 
agreement with a study from China which reported 
that the rate of T1762/A1764 mutation was 35% in 
genotype D of hepatitis B (43). A total of 77.3% 
HBeAg negative mutants of A1762T and G1764A in 
the present study corresponds to the Poovorawan 
study that shows paired mutations from A to T at 
nucleotide 1762 and from G to A at nucleotide 1764, 
in 75% of HBeAg-negative patients (43). Changing 
the core promoter from T1762A to G1764A not only 
has a bearing on the HBeAg anti-HBe phenotype, but 
also will affect the function(s) of the X protein. These 
nucleotide changes cause K130M and V131I 
conversions. The wild-type sequence is part of a 
region which confers a serine protease inhibitor 
function of the x protein (44), which has been 
suggested to play an important role in 
transcriptional transactivation activity (45). 
Present study showed accompaniment of 
mutation at G1896A in 44 (36.66%) patients, 
A1762T, G1764A in 36.66% and 25% of patients 
infected with genotype D HBV respectively, that is 
similar to a recent report from Iran (46), as well as a 
study from Thailand (47). In agreement with our 
results, a study from Germany which was done on 
HBeAg negative chronic hepatitis B patients, showed 
that the overall prevalence of the precore stop codon 
mutant and basal core promoter mutant was 46% 
and 59%, respectively. Genotype A and D are the 
major strains in Germany (48). It has been also 
determined in China that 38% of the HBeAg-negative 
patients harbored the pre-core stop codon (G1896A), 
42% had the BCP mutation of A1762T/G1764A, 
while 12% had both the BCP double mutation and 
the PCG1896A mutation after HBeAg seroconversion 
(49). Similar results have been observed in Thailand 
(50). Lower rate of mutation in pre-core (58.0%) and 
basal core promotor (25.3%) regions were reported 
from the UAE in which 94.3% of patients were 
HBeAg-negative (30).  
The 8bp deletion mutation in nucleotide1763-
1770 was observed in 7 (5.8%) of HBeAg negative 
patients. This mutation has been reported by 
Moriyama et al (51). This 8 bp deletion was shown 
by Unchida et al (52) and Kohno et al (53) at 1770-
1777 and 1768-1775, respectively. It is suggested 
that these mutations create a C-terminally truncated 
X protein, and probably mutation of the enhancer 
II/core promoter element (52).The reduction of 
HBeAg is due to both the reduced pre-core promoter 
activity and the defect in HBx (53). 
Deletions in core promoter (CP) region have been 
found in patients with chronic hepatitis B, in 
asymptomatic carriers, anti-HBe positive infection and 
HCC (54-56). The core promoter deletion mutant is 
characterized alone by low-level viremia (57). Most CP 
deletions are around 18bp to 21bp and have been 
found to be in BCP region. We did not see any mutation 
in our patients. These deletions usually involve the first 
and second AT rich regions and overlap some 
transcription factor binding sites; therefore, these 
mutations may affect the expression and function of 
HBx protein, and mostly result in a frame shift and 
truncation of the HBx at its C-terminal end which is 
essential for transactivating activity (57). 
Amino acid substitutions in the core gene at amino 
acid 64 and 69 were much more common in anti-HBe 
positive samples with the pre-core stop-codon 
mutation. Most of reports show low rate of mutation at 
these positions (58). However, we have shown high 
rate amino acid substitution as it was observed in 102 
(85%) and 99 (82.5%) patients at A64S and D69E, 
respectively. 
The results of this study indicate that the average 
rate of stop codon mutations in PC and double 
mutations in BCP in Golestan province of Iran were 
similar to the other reports from Iran (43) and other 
countries (22, 27, 28, 59). These mutations were 
specially found in HBeAg negative patients, as shown in 
the results of this study, which may help HBV to expand 
its viral proteins, and promote cancer development. 
 
Conclusion  
The average rate of stop codon mutations in PC 
and double mutations in BCP in Golestan province of 
Iran were similar to the reports from Iran and other 
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countries. These mutations were specially found in 
HBeAg negative patients. X gene protein was found 
to display various types of biological activities, but its 
specific role of wild and mutant forms in the 
pathogenesis of liver cancer has yet to be elucidated. 
The clinical and virological significance of PC and 
BCP mutations are yet to be fully understood, 
Further studies are necessary to elucidate the exact 
role of these mutations in the clinical course of HBV 
infection. 
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